Sugi Predict

Sugi Predict / Compounds / SCHEMBL605593

SCHEMBL605593

SCHEMBL605593

NC(=O)c1ccccc1N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 1.00
▸ HTT P42858 2/20 0.63
▸ KDM4E B2RXH2 3/20 0.60
▸ MAPT P10636 3/20 0.60
▸ HSD17B10 Q99714 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ THRB P10828 1/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ GFER P55789 1/20 0.60
▸ YWHAG P61981 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ KEAP1 Q14145 1/20 0.53
▸ CDC7 O00311 2/20 0.51
▸ CDK9 P50750 1/20 0.51
▸ L3MBTL1 Q9Y468 5/20 0.50
▸ NPSR1 Q6W5P4 3/20 0.50
▸ ATM Q13315 2/20 0.50
▸ TSHR P16473 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083169 1.00 NPC1 (1.00) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL31565663 0.98 NPC1 (0.96) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL3654065 0.98 NPC1 (0.96) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL17009548 0.94 NPC1 (0.89) NPC1HTTKDM4EMAPTHSD17B10
Trifluoroacetic Acid SCHEMBL5104669 0.89 NPC1 (0.79) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL7101608 0.86 NPC1 (0.76) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL3961543 0.85 NPC1 (0.72) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL7102897 0.84 NPC1 (0.73) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL2505914 0.84 NPC1 (0.73) NPC1HTTKDM4EMAPTHSD17B10
SCHEMBL227731 0.83 NPC1 (0.71) NPC1HTTKDM4EALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE METREA BIOSCIENCES INC (US) 2025-03-20 — — US claimed
US-9580438-B2 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders 4SC DISCOVERY GMBH (DE) 2017-02-28 — — US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 — — US claimed
US-20100105727-A1 NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF DONG-A-PHARM. CO., LTD. (KR) 2010-04-29 — — US claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 — — EP claimed
EP-2137152-A1 NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Dong-A Pharm.Co., Ltd. (KR) 2009-12-30 — — EP claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 — — EP claimed
US-7429603-B2 Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2008-09-30 — — US claimed
WO-2008114971-A1 NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF DONG-A PHARM. CO., LTD. (KR) 2008-09-25 — — WO claimed
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 — — US claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 — — WO claimed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 — — EP claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 — — US claimed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 — — WO claimed
EP-1631560-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-03-08 — — EP claimed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 — — US claimed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 — — US claimed
WO-2004096795-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2004-11-11 — — WO claimed
EP-1242396-A1 NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES AstraZeneca AB (SE) 2002-09-25 — — EP claimed
WO-2001044213-A1 NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES ASTRAZENECA AB (SE) 2001-06-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR NPC1 4199/4885HTT 2073/4885KDM4E 1410/4885
US-20100105727-A1 NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF HTR4, HTR1A, TPH1 NPC1 2292/4885HTT 813/4885KDM4E 2301/4885
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER NPC1 4368/4885HTT 2335/4885KDM4E 1464/4885
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE LPL, LIPA, PNLIP NPC1 330/4885HTT 1861/4885KDM4E 4122/4885
US-20050004112-A1 C-fms kinase inhibitors FLT3, FGR, FER NPC1 4334/4885HTT 2398/4885KDM4E 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.